Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 11/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.48 |
| ▸ | PARP1 | P09874 | 3/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25031342 | 0.94 | DDB1 (0.58) | DDB1CRBNHRH3PARP1TNKS | |
| SCHEMBL30830646 | 0.94 | DDB1 (0.60) | DDB1CRBNHRH3PARP1TNKS | |
| SCHEMBL29197146 | 0.90 | DDB1 (0.64) | DDB1CRBNHRH3 | |
| SCHEMBL30923323 | 0.90 | DDB1 (0.52) | DDB1CRBNHRH3PARP1TNKS | |
| SCHEMBL25031300 | 0.90 | DDB1 (0.52) | DDB1CRBNHRH3PARP1TNKS | |
| SCHEMBL26641205 | 0.86 | CRBN (0.59) | DDB1CRBN | |
| SCHEMBL30135914 | 0.85 | CRBN (0.48) | DDB1CRBNHRH3 | |
| SCHEMBL24880668 | 0.85 | DDB1 (0.50) | DDB1CRBNHRH3PARP1TNKS | |
| SCHEMBL30112339 | 0.85 | DDB1 (0.50) | DDB1CRBNHRH3PARP1TNKS | |
| SCHEMBL31487408 | 0.85 | DDB1 (0.58) | DDB1CRBNCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116322700-B | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-08-20 | — | — | CN | disclosed |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
| CN-116322700-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2023-06-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | DDB1 132/4885CRBN 2136/4885HRH3 4250/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | DDB1 77/4885CRBN 2496/4885HRH3 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.